Credit Suisse analyst Vamil Divan downgraded Eli Lilly to Neutral saying the valuation looks full with the shares up 13% since mid-August. The analyst sees limited drivers for further upside. He expects Lilly’s sales growth to be flat in 2018 due to patent expiration before returning to growth. Divan keeps an $88 price target for the shares. Lilly closed yesterday down 3c to $87.05.
Top Entertainment
Search
New Posts
Want to see butterflies in your backyard? Try doing less yardwork
A hidden danger lurks beneath Yellowstone
Why fuzzy definitions are a problem in the social sciences
Louis Pasteur’s devotion to truth transformed what we know about health and disease
A new book asks: What makes humans call some animals pests?
Leave A Comment